Pulsenmore

Pulsenmore Debt/EBITDA

The Total Debt to EBITDA Ratio of Pulsenmore (PLSM.TA) as of Nov 17, 2026 is -0.13. In the previous year, Total Debt to EBITDA Ratio was -0.08 — a change of 57.29% (lower).

Debt/EBITDA

-0.13

YoY

57.29%

Last updated:

Total Debt to EBITDA Ratio of Pulsenmore is 2025 -0.13 . Total Debt to EBITDA Ratio of Pulsenmore was 2024 -0.08 . It decreases by 57.29% lower compared to the previous year.

The Pulsenmore Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2019
-0.54 ILS
Jan 1, 2020
-0.08 ILS
Jan 1, 2021
-0.04 ILS
Jan 1, 2022
-0.16 ILS
Jan 1, 2023
-0.11 ILS
Jan 1, 2024
-0.08 ILS
Jan 1, 2025
-0.13 ILS
The Pulsenmore Debt/EBITDA history
YEARDebt/EBITDAYoY
-0.13+57.29%
-0.08-23.55%
-0.11-31.66%
-0.16+285.22%
-0.04-51.50%
-0.08-84.36%
-0.54—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pulsenmore Stock analysis

What does Pulsenmore do? Pulsenmore Ltd. generates revenue through the sale of its two miniaturized ultrasound systems, PulseNmore ES and PulseNmore FC, designed for home use in remote clinical diagnosis. The PulseNmore ES targets pregnant women requiring regular ultrasound monitoring, while PulseNmore FC caters to women undergoing in vitro fertilization needing follicle size assessments. Both systems integrate with smartphones, enabling patients to conduct tests at home and share results online with healthcare providers. The company also monetizes through software delivery for its devices, enhancing user experience and data management. The primary buyers of PulseNmore ES are pregnant women seeking convenient, clinic-free monitoring, and healthcare providers managing prenatal care remotely. PulseNmore FC is purchased by women undergoing in vitro fertilization, often through fertility clinics or medical centers that recommend the device. These segments value the convenience of home-based diagnostics and seamless telehealth integration without requiring in-person visits. Pulsenmore Ltd. focuses on global markets for its portable ultrasound solutions, serving patients in remote or underserved areas who benefit from telehealth-enabled diagnostics. The company’s products are positioned as cost-effective alternatives to traditional clinic visits, appealing to both end-users and healthcare institutions aiming to reduce operational costs while maintaining patient care quality. Pulsenmore is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pulsenmore stock

Total Debt to EBITDA Ratio of Pulsenmore is -0.13 in 2025.

Total Debt to EBITDA Ratio of Pulsenmore changed from -0.08 to -0.13, representing a 57.29% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Pulsenmore since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Pulsenmore with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Pulsenmore

All Key Metrics — Pulsenmore